The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
|Videos|August 23, 2017
Dr. Hammers on Next Steps with Immunotherapy in RCC
Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the next steps with immunotherapy for patients with renal cell carcinoma (RCC).
Advertisement
Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the next steps with immunotherapy for patients with renal cell carcinoma (RCC).
Data are still needed to determine the response of nivolumab (Opdivo) in certain subsets of patients, states Hammers. If there is a signal of clinical activity, it might be studied in combination with other regimens for this patient population.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
FDA grants priority review to durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC based on positive phase 3 VOLGA data.
The FDA has approved belzutifan (Welireg) plus lenvatinib (Lenvima) for use in patients with advanced renal cell carcinoma with a clear cell component after PD-1 or PD-L1 inhibition.
The CHMP recommended perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer.
Advertisement
Advertisement
Trending on OncLive
1
Savolitinib Plus Osimertinib NDA Submitted to FDA for MET-Driven, EGFR-Mutated NSCLC After EGFR TKI
2
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
3
Calculating the Real Cost of False Positive Findings in Cancer Screening
4
Cilta-Cel Shows Long-Term Treatment-Free Remissions in Lenalidomide-Refractory Myeloma
5